MUC2-KLH conjugate vaccine (Memorial Sloan-Kettering Cancer Center)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMUC2-KLH conjugate vaccine (Memorial Sloan-Kettering Cancer Center)

Drug Alias NameMUC2-KLH conjugate vaccine (prostate cancer)MUC2-KLH

ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Conjugated vaccineVaccines > Biological material > Bacterial vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMemorial Sloan Kettering Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMemorial Sloan Kettering Cancer Center

Active IndicationsN/A

Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A